# Liquisolids as a platform for the formulation of cannabis tablets

**Authors:** Jan Appelhaus, Karl G. Wagner, Kristina E. Steffens

PMC · DOI: 10.1016/j.ijpx.2026.100508 · International Journal of Pharmaceutics: X · 2026-02-24

## TL;DR

This paper presents a new method to make cannabis tablets using liquisolids, which allows for stable and effective solid dosage forms of sticky cannabis extracts.

## Contribution

The study introduces an optimized formulation and production strategy for cannabis liquisolid tablets with long-term stability and high liquid load.

## Key findings

- A 65/35 ratio of Syloid® XDP 3050 and Vivapur® 101 enabled successful tableting of viscous cannabis extracts.
- Cannabis tablets showed a tensile strength of 1.58 N/mm² and a high Overall Liquid Load of 38.4% (V/V).
- The tablets remained stable for 30 days at 40°C and 0% humidity, with predicted stability >3 years under refrigeration.

## Abstract

Mesoporous silica-based liquisolids offer an effective method for transforming liquid or sticky actives, such as cannabis extracts, into free-flowing powders. This approach broadens the formulation strategies available for these actives, which are typically limited to liquid formulations or soft gelatin encapsulation, by facilitating the formulation of tablets. However, tableting liquisolids is challenging due to issues including low tensile strength, capping and delamination. Overcoming these challenges requires careful selection of excipients and tableting parameters to produce tablets with sufficient tensile strength while also maintaining high Overall Liquid Load. In our study, we utilized a 65/35 volumetric ratio of 0.75 mL/g liquid loaded Syloid® XDP 3050 silica and Vivapur® 101 as a binder/filler to formulate cannabis liquisolid tablets with a target THC dose of 10 mg per tablet. Findings indicated that a 4% concentration of Kollidon® CL-F was optimal for disintegration, while 0.5% magnesium stearate proved to be the most effective lubricant concentration. Utilizing a rotary press compaction cycle on a StylOne® compaction simulator, we found precompression around half the main compaction pressure allowed for maximizing tableting speed while maintaining high tensile strength and keeping tablet defects to a minimum. The resulting cannabis liquisolid tablets demonstrated a tensile strength of 1.58 N/mm2 and a high Overall Liquid Load of 38.4% (V/V). They exhibited acceptable disintegration time, friability, dissolution behavior and were proven to remain stable for 30 days at 40 °C and 0% humidity. Under refrigerated conditions, stability is predicted to be >3 years.

Unlabelled Image

•A 65/35 ratio of Syloid® XDP 3050 to Vivapur® 101 enables tableting of viscous cannabis extracts.•Precompression pressure and tableting speed are critical process parameters for liquisolid tablet production.•Sticky and highly viscous extracts can be formulated into tablets using the proposed formulation and production strategy.•Cannabis tablets are predicted to be stable for >3 years under refrigerated conditions.

A 65/35 ratio of Syloid® XDP 3050 to Vivapur® 101 enables tableting of viscous cannabis extracts.

Precompression pressure and tableting speed are critical process parameters for liquisolid tablet production.

Sticky and highly viscous extracts can be formulated into tablets using the proposed formulation and production strategy.

Cannabis tablets are predicted to be stable for >3 years under refrigerated conditions.

## Linked entities

- **Chemicals:** THC (PubChem CID 16078)

## Full-text entities

- **Diseases:** wasting (MESH:D019282), pain (MESH:D010146), cancer (MESH:D009369), insomnia (MESH:D007319), anorexia (MESH:D000855), migraine (MESH:D008881), multiple sclerosis (MESH:D009103), cognitive impairment (MESH:D003072)
- **Chemicals:** water (MESH:D014867), magnesium stearate (MESH:C031183), glacial acetic acid (MESH:D019342), isopropyl alcohol (MESH:D019840), crospovidone (MESH:D011205), 1-Decanol (MESH:C029383), propylene carbonate (MESH:C045990), Sativex (MESH:C587251), ethanol (MESH:D000431), sodium chloride (MESH:D012965), PTFE (MESH:D011138), phosphate (MESH:D010710), Dronabinol (MESH:D013759), Vivapur (MESH:C477445), Nitrogen (MESH:D009584), acetonitrile (MESH:C032159), CBDA (MESH:C006884), carbamazepine (MESH:D002220), MCC (MESH:C109691), cellulose (MESH:D002482), simvastatin (MESH:D019821), polysorbates (MESH:D011136), 6-O-palmitoyl ascorbic acid (MESH:C031226), Cannabinoid (MESH:D002186), CBD (MESH:D002185), bile salts (MESH:D001647), prednisolone (MESH:D011239), naproxen (MESH:D009288), 6-O-palmitoly ascorbic acid (-), disodium phosphate heptahydrate (MESH:C018279), silica (MESH:D012822), trifluoroacetic acid (MESH:D014269)
- **Species:** Scopus (genus) [taxon 33580], Cannabis (genus) [taxon 3482], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955684/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955684/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955684/full.md

---
Source: https://tomesphere.com/paper/PMC12955684